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Abstract 
Gomisin N, which is a lignan isolated from Schisandra chinensis, has some pharmacological 
effects. However, the anti-inflammatory effects of gomisin N on periodontal disease are 
uncertain. The aim of this study was to examine the effect of gomisin N on inflammatory 
mediator production in tumor necrosis factor (TNF)-α-stimulated human periodontal 
ligament cells (HPDLC). Gomisin N inhibited interleukin (IL)-6, IL-8, CC chemokine ligand 
(CCL) 2, and CCL20 production in TNF-α-stimulated HPDLC in a dose-dependent manner. 
Moreover, we revealed that gomisin N could suppress extracellular signal-regulated kinase 
(ERK) and c-Jun N terminal kinase (JNK) phosphorylation in TNF-α-stimulated HPDLC 
though protein kinase B (Akt) phosphorylation was not suppressed by gomisin N treatment. 
In summary, gomisin N might exert antiinflammatory effects by attenuating cytokine 
production in periodontal ligament cells via inhibiting the TNF-α-stimulated ERK and JNK 
pathways activation.  
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Introduction  
Gomisin N is a bioactive compound isolated from Schisandra chinensis, which is used for 
traditional chinese medicine to treat diabetes, asthma, and respiratory infection. Gomisin N 
exerts a variety of pharmacological effects, including anti-inflammation [1] and anti-cancer 
effect [2]. Previous study showed that gomisin N suppresses PMA-induced inflammatory 
response in bone marrow-derived mast cells by inhibiting IL-6, prostaglandin D2, leukotriene 
C4, and cyclooxygenase-2 [3]. Another report showed that gomisin N enhances tumor 
necrosis factor α-induced apoptosis in HeLa cell [4]. This result showed that gomisin N 
might be use for an anti-cancer drug. However, it is uncertain whether gomisin N has 
anti-inflammatory effects on periodontal resident cells.  
Periodontal disease is an infectious inflammatory disease induced by periodontal pathogenic 
bacteria. Host response to the bacteria is essential for the initiation and progression of 
periodontal disease [5]. Inflammatory cytokines from periodontal resident cells are important 
to explain the pathogenesis of periodontitis [5]. Interleukin (IL)-6 is involved in the 
activation of osteoclast in periodontal lesion [6]. Chemokines, such as IL-8, CCL2, and 
CCL20, induce the migration and accumulation of leukocytes, including neutrophils [7], 
macrophages [8], and Th17 cells [9]. Therefore, the inhibition of too much cytokine 
production could lead the relief of inflammation in periodontal lesion.  
The aim of this study was to examine the effect of gomisin N on IL-6, IL-8, CCL2, and 
CCL20 production from TNF-α-stimulated human periodontal ligament cells (HPDLC) 
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Moreover, we examined if gomisin N treatment modified the activation of p38 mitogen 
activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and c-Jun N 
terminal kinase (JNK), and protein kinase B (Akt) pathway in TNF-α-stimulated HPDLCs.  
Materials and Methods 
Cell culture. 
Human primary periodontal ligament cells were obtained from Lonza Japan Ltd (Chuo-ku, 
Tokyo, Japan) and grown in the Dulbecco’s modified Eagle’s medium (DMEM: Sigma, St. 
Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; JRH Biosciences, 
Lenexa, KS), 1 mmol/L sodium pyruvate (Gibco) and, antibiotics (penicillin G: 100 units/ml, 
streptomycin: 100µg/ml: Gibco) at 37OC in a humidified air with 5% CO2. HPDLC were 
seeded in 24-well plates at a density of 1×105 cells per well for ELISA or in 12-well plates 
at a density of 3×105 per well for western blot analysis. We used HPDLC for our 
experiments after confluence. Cells were used between passage numbers 5 and 10. 
IL-6, IL-8, CCL2, and CCL20 production in HPDLC. 
The HPDLC were stimulated with recombinant human TNF-α (10 ng/ml: Peprotech, Rocky 
Hill, NJ, USA) for 24 hours. The supernatants from the HPDLC were collected, and the IL-6, 
IL-8, CCL2, and CCL20 concentrations in the culture supernatants were measured in 
triplicate with ELISA. Duoset (R&D systems, Minneapolis, MN, USA) was used for the 
determination. All assays were performed according to the manufacturer’s instructions, and 
cytokine levels were determined using the standard curve prepared for each assay. In selected 
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experiments, the HPDLC were cultured for 1 hour in the presence or absence of gomisin N 
(3.125, 6.25, 12.5, 25, or 50 µM: Nagara Science Co., Ltd., Gifu, Japan), SB203580 (p38 
MAPK inhibitor, 10 µM: Santa Cruz Biotechnology, Santa Cruz, CA, USA), PD98059 (ERK 
inhibitor, 10 µM: Cayman Chemical, Ann Arbor, MI, USA), SP600125 (JNK inhibitor, 10 
µM: Enzo Life Sciences, Plymouth Meeting, PA, USA), or 10-DEBC hydrochloride (Akt 
inhibitor, 1 µM: Santa Cruz Biotechnology) prior to the incubation with TNF-α (10 ng/ml). 
Western blot analysis 
To detect the TNF-α-induced phosphorylation of signal transduction molecules, western blot 
analysis was performed. HPDLC stimulated by TNF-α (10 ng/ml) with or without gomisin N 
(12.5 µM or 25 µM) pretreatment for 1 hour were washed once with cold PBS, before being 
incubated on ice for 30 min with cell lysis buffer (Cell signaling technology, Danvers, MA, 
USA) supplemented with protease inhibitors cocktail (Sigma). After removal of debris by 
centrifugation, the protein concentrations of the lysates were quantified with the Bradford 
protein assay using IgG as a standard. A 20 µg protein sample was loaded onto a 4-20% 
SDS-PAGE gel, before being electrotransfered to a PVDF membrane. The phosphorylation 
of p38 MAPK, ERK, JNK, and Akt was assessed using phospho-p38 MAPK rabbit 
monoclonal antibody (Cell Signaling Technology), phospho-ERK rabbit monoclonal 
antibody (Cell Signaling Technology), phospho-JNK rabbit monoclonal antibody (Cell 
Signaling Technology), phospho-Akt rabbit monoclonal antibody (Cell Signaling 
Technology), p38 MAPK rabbit monoclonal antibody (Cell Signaling Technology), ERK 
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rabbit monoclonal antibody (Cell Signaling Technology), JNK rabbit monoclonal antibody 
(Cell Signaling Technology), Akt mouse monoclonal antibody (Cell Signaling Technology), 
or glyceraldehyde-3-phosphate dehydrogenasee (GAPDH) rabbit monoclonal antibody (Cell 
Signaling Technology) according to the manufacturer’s instructions. Protein bands were 
visualized by incubation with the HRP-conjugated secondary antibody (Sigma), followed by 
detection using the ECL Prime Western Blotting Detection System (GE Healthcare, Uppsala, 
Sweden). Each chemiluminescent signal was quantified by the ImageJ software (version 
1.44). 
Statistical analysis. 
Statistical significance was analyzed using the Student’s t test. P values<0.05 were 
considered significant in Fig.1 and 3. 
Results 
Effects of gomisin N on IL-6, IL-8, CCL2, and CCL20 production in TNF-α-stimulated 
HPDLC.  
To examine the anti-inflammatory effects on gomisin N, IL-6, IL-8, CCL2, and CCL20 
productions were measured using ELISA. Fig.1 shows that TNF-α stimulation induced IL-6, 
IL-8, CCL2, and CCL20 in HPDLCs. Treatment of gomisin N significantly suppressed IL-6, 
IL-8, CCL2, and CCL20 productions in a dose-dependent fashion (Fig.1) Method of 
transcriptional and translational (MTT) assays revealed treatment with 25 or 50 μM of 
gomisin N for 24 h did not modulate HPDLC viability (data not shown). 
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Effects of gomisin N on MAPKs and Akt activations in TNF-α-stimulated HPDLC 
MAPKs and Akt signaling pathways play essential roles in the regulation of cytokine and 
chemokine productions in some types of cells [10, 11]. Therefore, we investigated if the 
anti-inflammatory effects of gomisin N resulted from the inhibition of MAPKs and Akt 
pathways. Fig.2 shows that gomisin N ( 25 μM) treatment suppressed ERK and JNK 
phosphorylation in TNF-α-stimulated HPDLC. 
Effects of MAPKs and Akt inhibitors on IL-6, IL-8, CCL2, and CCL20 productions in 
TNF-α-stimulated HPDLC. 
Finally, we investigated which signaling pathways are related with IL-6, IL-8, CCL2, and 
CCL20 production in TNF-α-stimulated HPDLCs using chemical inhibitors. A p38 inhibitor 
(SB203580) and an ERK inhibitor (PD98059) significantly suppressed IL-6, IL-8, CCL2, and 
CCL20 productions in TNF-α-stimulated HPDLC. A JNK inhibitor (SP600125) inhibited 
IL-6, IL-8, and CCL2 productions though CCL20 production was not changed by a JNK 
inhibitor (SP600125) treatment. An Akt inhibitor significantly decreased IL-8 and CCL2 
productions though IL-6 and CCL20 productions from TNF-α-stimulated HPDLC were not 
modified.  
Discussion 
Immune response to the bacteria is important for the initiation and progression of periodontal 
disease [5]. Inflammatory cytokines are related to bone resorption in periodontal lesion [12]. 
Leukocytes, such as T cells and macrophages, are involved in the pathogenesis of periodontal 
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disease [13], and chemokines are essential for the accumulation of leukocytes in 
inflammatory lesion [14]. Therefore, the inhibition of cytokine and chemokines in 
periodontal lesion is important for the treatment of periodontal disease. In this study, gomisin 
N could decrease IL-6, IL-8, CCL2, and CCL20 productions in HPDLC which is a resident 
cell in periodontal tissue. IL-6 is related to the activation and differentiation of osteoclasts in 
periodontal lesion [6]. IL-8 is able to induce neutrophils accumulation [7]. It is certain that 
neutrophils could induce bone resorption in periodontal diseased tissue [14]. CCL2 and 
CCL20 are chemokines that are related to macrophages and Th17 cells migration and 
accumulation [9, 10]. It is certain that Th17 cells are important T cell subsets to explain bone 
destruction in inflammatory disease, such as arthritis [9] or periodontitis [16]. In this study, 
gomisin N significantly suppressed IL-6, IL-8, CCL2, and CCL20 productions from TNF-α
-stimulated HPDLC. This result means that gomisin N might protect bone destruction in 
periodontal lesion. Further investigation using animal model is necessary to address this 
hypothesis. 
In this study, we showed gomisin N could inhibit MAPKs activations in TNF-α-stimulated 
HPDLC. Previous manuscripts reported the effect of gomisin N on MAPKs phosphorylation. 
Waiwut and the colleagues reported that gomisin N could suppress p38 MAPK 
phosphorylation in TNF-α-treated Hela cells [4]. Park and the colleagues reported that 
gomisin N inhibited p38 MAPK and JNK phosphorylation in toll-like receptor (TLR) 2 and 4 
agonists stimulated microglia [17]. They also showed that gomisin N did not modulate ERK 
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activation in TLR 2/4 agonists treated microglia [17]. We revealed gomisin N suppressed 
ERK and JNK phosphorylation in TNF-α-treated HPDLC. We think the effect of gomisin N 
on MAPKs activation is dependent on the type of cells and stimulants.  
In summary, this report shows that gomisin N could inhibit inflammatory mediators, 
including IL-6, IL-8, CCL2, and CCL20, productions in HPDLC through inhibition of TNF-
α-induced ERK and JNK activation. Further study should be necessary to address the 
question whether we can use gomisin N for the treatment of periodontal disease.  
Acknowledgements 
This work was supported by JSPS KAKENHI (Grant Numbers: 16K11834 and 15K11392). 
Conflict of interest 
The authors confirm that they are no conflicts of interest. 
Figure Legends 
Fig.1. Effects of gomisin N on IL-6, IL-8, CCL2, and CCL20 production from 
TNF-α-stimulated HPDLC. HPDLC were pretreated with gomisin N (3.125, 6.25, 12.5, 25, 
or 50 µΜ) for 1 hour, and then the HPDLC were stimulated with TNF-α (10 ng/ml), and the 
supernatants were collected after 24 hours. The expression levels of IL-6, IL-8, CCL2, and 
CCL20 in the supernatants were measured using ELISA. The results are shown as the mean 
and SD of one representative experiment performed in triplicate. The error bars show the SD 
of the values. * = P<0.05, significantly different from the TNF-αstimulated HPDLC without 
gomisin N. 
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Fig.2. Effects of gomisin N on p38 MAPK, ERK, JNK, and Akt phosphorylation in 
TNF-α-stimulated HPDLC.  HPDLC were pretreated with gomisin N (12.5 or 25 µΜ) for 
1 hour, and then the HPDLC were stimulated with TNF-α (10 ng/ml), and proteins were 
collected after 15, 30, or 60 minutes. Phospho-p38 MAPK, total-p38 MAPK, phospho-ERK, 
total-ERK, phospho-JNK, total-JNK, phospho-Akt, and total-Akt were determined by 
western blot analysis. We show a representative data from three independent experiments.  
Fig.3. Effects of MAPK inhibitors and Akt inhibitor on IL-6, IL-8, CCL2, and CCL20 
production from TNF-α-stimulated HPDLC. HPDLC were pretreated with SB203580 
(p38 MAPK inhibitor, 10 μM), PD98059 (ERK inhibitor, 10 μM), SP600125 (JNK 
inhibitor, 10 μM), or 10-DEBC hydrochloride (Akt inhibitor, 1 μM) for 1 hour, and then 
HPDLC were stimulated with TNF-α (10 ng/ml), and the supernatants were collected after 
24 hours. The production levels of IL-6, IL-8, CCL2, and CCL20 in the supernatants were 
measured using ELISA. The results are shown as the mean and SD of one representative 
experiment performed in triplicate. The error bars show the SD of the values. * = P<0.05, 
significantly different from the TNF-αstimulated HPDLC without chemical inhibitors. 
 
References 
1. Oh SY, Kim YH, Bae DS, Um BH, Pan CH, Kim CY, Lee HJ, Lee JK. 
Anti-inflammatory effects of gomisin N, gomisin J, and schisandrin C isolated 
from the fruit of Schisandra chinensis. Biosci Biotechnol Biochem. 2010; 74: 
 11 
285-91. 
2. Yim SY, Lee YJ, Lee YK, Jung SE, Kim JH, Kim HJ, Son BG, Park YH, Lee YG, 
Choi YW, Hwang DY. Gomisin N isolated from Schisandra chinensis significantly 
induces anti-proliferative and pro-apoptotic effects in hepatic carcinoma. Mol Med 
Rep. 2009; 2: 725-32.  
3. Chae HS, Kang OH, Oh YC, Choi JG, Keum JH, Kim SB, Kim YS, Mun SH, Shin 
DW, Han SH, Kwon DY. Gomisin N has anti-allergic effect and inhibits 
inflammatory cytokine expression in mouse bone marrow-derived mast cells. 
Immunopharmacol Immunotoxicol. 2011; 33: 709-13. 
4. Waiwut P, Shin MS, Inujima A, Zhou Y, Koizumi K, Saiki I, Sakurai H. Gomisin N 
enhances TNF-α-induced apoptosis via inhibition of the NF-κB and EGFR survival 
pathways. Mol Cell Biochem. 2011;350:169-75. 
5. Graves D. Cytokines that promote periodontal tissue destruction. J Periodontol. 
2008 ;79:1585-91. 
6. Sims NA, Walsh NC. GP130 cytokines and bone remodelling in health and disease. 
BMB Rep. 2010;43:513-23. 
7. Bickel M. The role of interleukin-8 in inflammation and mechanisms of regulation. J 
Periodontol. 1993;64:456-60. 
8. Mantovani A, Sozzani S, Bottazzi B, Peri G, Sciacca FL, Locati M, Colotta F. 
Monocyte chemotactic protein-1 (MCP-1): signal transduction and involvement in 
 12 
the regulation of macrophage traffic in normal and neoplastic tissues. Adv Exp 
Med Biol. 1993;351:47-54. 
9. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, 
Yamaguchi T, Nomura T, Ito H, Nakamura T, Sakaguchi N, Sakaguchi S. 
Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via 
CCL20 in rheumatoid arthritis and its animal model. J Exp Med. 
2007;204:2803-12. 
10. Kyriakis JM. Activation of the AP-1 transcription factor by inflammatory cytokines 
of the TNF family. Gene Expr. 1999;7:217-31. 
11. Hazeki K, Nigorikawa K, Hazeki O. Role of phosphoinositide 3-kinase in innate 
immunity. Biol Pharm Bull. 2007;30:1617-23. 
12. Souza PP, Lerner UH. The role of cytokines in inflammatory bone loss. Immunol 
Invest. 2013;42:555-622. 
13. Taubman MA, Kawai T. Involvement of T-lymphocytes in periodontal disease and 
in direct and indirect induction of bone resorption. Crit Rev Oral Biol Med. 
2001;12:125-35. 
14. Silva TA, Garlet GP, Fukada SY, Silva JS, Cunha FQ. Chemokines in oral 
inflammatory diseases: apical periodontitis and periodontal disease. J Dent Res. 
2007;86:306-19. 
15. Van Dyke TE, Hoop GA. Neutrophil function and oral disease. Crit Rev Oral Biol 
 13 
Med. 1990;1:117-33. 
16. Cheng WC, Hughes FJ, Taams LS. The presence, function and regulation of IL-17 
and Th17 cells in periodontitis. J Clin Periodontol. 2014;41:541-9. 
17. Park SY, Bae YS, Ko MJ, Lee SJ, Choi YW. Comparison of anti-inflammatory 
potential of four different dibenzocyclooctadiene lignans in microglia; action via 
activation of PKA and Nrf-2 signaling and inhibition of MAPK/STAT/NF-κB 
pathways. Mol Nutr Food Res. 2014;58:738-48. 
 
 14 
 
 
 15 
 
 
 16 
 
